Combining 2D angiogenesis and 3D Osteosarcoma microtissues to improve vascularization

Date 21 October 2018
Event ESMO 2018 Congress
Session Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Topics Bone Sarcomas
Cancer Biology
Presenter Hassan Chaddad
Citation Annals of Oncology (2018) 29 (suppl_8): viii670-viii682. 10.1093/annonc/mdy304
Authors H.M. Chaddad
  • Regenerative Nanomedecine, Faculte de medecine de strasbourg, 67000 - Strasbourg/FR



The number of patients suffering from cancers worldwide is increasing, and one of the most challenging issues in oncology continues to be the problem of developing active drugs economically and in a timely manner. Considering the high cost and time-consuming nature of the clinical development of oncology drugs, better pre-clinical platforms for drug screening are urgently required. So, there is a need for high-throughput drug screening platforms to mimic the in vivo microenvironment. Angiogenesis is now well known for being involved in tumor progression, aggressiveness, emergence of metastases, and also resistance to cancer therapies.


In this study, to better mimic tumor angiogenesis encountered in vivo, we used 3D culture of osteosarcoma cells (MG-63) that we deposited on 2D endothelial cells (HUVEC) grown in monolayer. Combination 2D HUVEC/3D MG-63 was characterised by Indirect immunofluorescence, scanning electron microscopy, optical microscopy and mRNA expression (qPCR).


We report that endothelial cells combined with tumor cells were able to form a well-organized network, and those tubule-like structures correspond to new vessels infiltrating tumor spheroids. These vessels presented a lumen and expressed specific markers, such as CD31 and collagen IV. The combination of 2D endothelial cells and 3D microtissues of tumor cells also increased expression of angiogenic factors as VEGF, CXCR4 and ICAM1.


The cell environment is the key point to develop tumor vascularization in vitro and to be closer to the tumor encountered in vivo.

Clinical trial identification

Legal entity responsible for the study

Inserm 1260, Regenerative nanomedecine.


Agence Nationale de la Recherche, ANR.

Editorial Acknowledgement


The author has declared no conflicts of interest.